ClinicalTrials.gg
CompletedNCT05040971STEP 10Updated Jan 29, 2026Results posted

Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

A Phase 3 interventional study of Semaglutide 2.4 mg and Placebo in Obesity, sponsored by Novo Nordisk A/S. Completed at 43 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
36th of 143
207 · median 100
Started
2021
with 9 others
Phase 3
42 of 143
10 open now
Registered
33rd of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 36th largest by enrollment, is one of 10 that started in 2021, is one of 42 in phase 3, and was the 33rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes.

This study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having normal blood sugar.

Semaglutide is compared to a "dummy" medicine. The "dummy" medicine looks like semaglutide but has no effect on the body.

In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight.

Participants will either get semaglutide or "dummy" medicine - which treatment they get is decided by chance. Participants are 2 times as likely to get semaglutide as "dummy" medicine.

Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.

The study will last for about 19 months. Participants have to take the study medicine every week for the first 12 months. The last 7 months participants will not take any medication.

Participants will have 14 clinic visits and 1 phone call with the study staff. At 9 of the clinic visits Participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged greater than or equal to 18 years at the time of signing .
  • greater than or equal to 30.0 kg/m\^2
  • Prediabetes defined as at least one of the following:

    • between 6.0 and 6.4 percent (42 and 47 mmol/mol) (both inclusive) as measured by central laboratory at screening.
    • FPG between 5.5 and 6.9 mmol/L (99 and 125 mg/dL) (both inclusive) as measured by central laboratory at screening.

Exclusion criteria

Exclusion Criteria:

  • History of type 1 or type 2 diabetes.
  • Treatment with glucose-lowering agent(s) within 90 days before screening.
  • greater than or equal to 6.5 percent (greater than or equal to 48 mmol/mol) as measured by central laboratory at screening.
  • FPG greater than or equal to 7.0mmol/L (126 mg/dL) as measured by central laboratory at screening.

A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records.

  • Treatment with any medication for the indication of obesity within the past 90 days before screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks

    Drug: Semaglutide 2.4 mg

  • Placebo comparator
    Placebo (semaglutide)

    Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks

    Drug: Placebo

Interventions

  • Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg

  • DrugPlacebo

    Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week

06

What researchers measure

Primary outcomes

  1. Change in Body Weight (Percentage [%])

    Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  2. Participants With Change to Normoglycemia

    Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: glycosylated haemoglobin (HbA1c) lesser than (\<) 6.0 percentage (%) and fasting plasma glucose (FPG) lesser than (\<) 5.5 millimoles per liter (mmol/L). 2) Pre-diabetes: 6.0% lesser than or equal (≤) HbA1c lesser than (\<) 6.5% or 5.5 mmol/L lesser than or equal (≤) FPG lesser than (\<) 7.0 mmol/L or non-verified type 2 diabetes. 3) Type 2 diabetes: HbA1c greater than or equal (≥) 6.5% or FPG greater than or equal (≥) 7.0 mmol/L.

    Time frame: At week 52

Secondary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change in glycosylated haemoglobin (HbA1c) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  2. Change in Fasting Plasma Glucose (FPG)

    Change in fasting plasma glucose (FPG) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  3. Change in Waist Circumference

    Change in waist circumference from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  4. Change in Systolic Blood Pressure

    Change in systolic blood pressure from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  5. Change in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

    Change in triglycerides (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  6. Change in Total Cholesterol (mmol/L) - Ratio to Baseline

    Change in total cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  7. Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  8. Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  9. Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in very low density lipoprotein (VLDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

  10. Change in Body Weight (Kilogram [Kg])

    Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to week 52

  11. Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 5% (Yes/No)

    Participants who achieved body weight reduction greater than or equal to 5% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: At week 52

  12. Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 10% (Yes/No)

    Participants who achieved body weight reduction greater than or equal to 10% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: At week 52

  13. Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 15% (Yes/No)

    Participants who achieved body weight reduction greater than or equal to 15% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: At week 52

  14. Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 20% (Yes/No)

    Participants who achieved body weight reduction greater than or equal to 20% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: At week 52

  15. Change in Pulse

    Change in pulse from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

    Time frame: From randomisation (week 0) to end of treatment (week 52)

07

Results

Posted Oct 28, 2024

Participant flow

The trial was conducted at 30 sites in 5 countries as follows: Canada (15 sites), Denmark (2 sites), Finland (2 sites), Spain (3 sites) and United Kingdom (8 sites).

Participant flow — Overall Study
MilestoneSemaglutide 2.4 mgPlacebo
Started13869
Full analysis set (fas)13869
Safety analysis set (sas)13869
Completed12864
Not completed105
Withdrew: Withdrawal by subject02
Withdrew: Lost to follow-up83
Withdrew: Death20

Outcome measures

PrimaryChange in Body Weight (Percentage [%])

Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Mean · Percentage (%) of body weight
Change in Body Weight (Percentage [%])
Percentage (%) of body weightSemaglutide 2.4 mgPlacebo
Change in Body Weight (Percentage [%])-14.4 ± 7.9-2.7 ± 4.3
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -11.19 · 95% CI -12.97 to -9.42
PrimaryParticipants With Change to Normoglycemia

Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: glycosylated haemoglobin (HbA1c) lesser than (\<) 6.0 percentage (%) and fasting plasma glucose (FPG) lesser than (\<) 5.5 millimoles per liter (mmol/L). 2) Pre-diabetes: 6.0% lesser than or equal (≤) HbA1c lesser than (\<) 6.5% or 5.5 mmol/L lesser than or equal (≤) FPG lesser than (\<) 7.0 mmol/L or non-verified type 2 diabetes. 3) Type 2 diabetes: HbA1c greater than or equal (≥) 6.5% or FPG greater than or equal (≥) 7.0 mmol/L.

Time frame:
At week 52
Reported as:
Count of participants · Participants
Participants With Change to Normoglycemia
ParticipantsSemaglutide 2.4 mgPlacebo
Normoglycemia1039
Pre-diabetes2353
Type 2 diabetes12
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 19.81 · 95% CI 8.68 to 45.21
SecondaryChange in Glycosylated Haemoglobin (HbA1c)

Change in glycosylated haemoglobin (HbA1c) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Mean · Percentage of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage of HbA1cSemaglutide 2.4 mgPlacebo
Change in Glycosylated Haemoglobin (HbA1c)-0.4 ± 0.30.1 ± 0.2
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in fasting plasma glucose (FPG) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Mean · millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG)
millimoles per liter (mmol/L)Semaglutide 2.4 mgPlacebo
Change in Fasting Plasma Glucose (FPG)-0.8 ± 0.6-0.3 ± 0.7
SecondaryChange in Waist Circumference

Change in waist circumference from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Mean · centimeter (cm)
Change in Waist Circumference
centimeter (cm)Semaglutide 2.4 mgPlacebo
Change in Waist Circumference-11.6 ± 8.7-2.8 ± 5.4
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Mean · millimeters of mercury (mmHg)
Change in Systolic Blood Pressure
millimeters of mercury (mmHg)Semaglutide 2.4 mgPlacebo
Change in Systolic Blood Pressure-9 ± 13-1 ± 13
SecondaryChange in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

Change in triglycerides (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline
Ratio of triglyceridesSemaglutide 2.4 mgPlacebo
Change in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline0.80 ± 36.40.96 ± 30.6
SecondaryChange in Total Cholesterol (mmol/L) - Ratio to Baseline

Change in total cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol (mmol/L) - Ratio to Baseline
Ratio of total cholesterolSemaglutide 2.4 mgPlacebo
Change in Total Cholesterol (mmol/L) - Ratio to Baseline0.94 ± 16.11.01 ± 15.7
SecondaryChange in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of HDL cholesterolSemaglutide 2.4 mgPlacebo
Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline1.02 ± 12.40.99 ± 11.7
SecondaryChange in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of LDL cholesterolSemaglutide 2.4 mgPlacebo
Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline0.93 ± 26.61.03 ± 23.6
SecondaryChange in Very Low Density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in very low density lipoprotein (VLDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Geometric mean · Ratio of VLDL cholesterol
Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of VLDL cholesterolSemaglutide 2.4 mgPlacebo
Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline0.80 ± 36.50.96 ± 30.7
SecondaryChange in Body Weight (Kilogram [Kg])

Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to week 52
Reported as:
Mean · kilogram (Kg)
Change in Body Weight (Kilogram [Kg])
kilogram (Kg)Semaglutide 2.4 mgPlacebo
Change in Body Weight (Kilogram [Kg])-15.8 ± 9.3-2.8 ± 5.0
SecondaryParticipants Achieving Body Weight Reduction Greater Than or Equal (≥) 5% (Yes/No)

Participants who achieved body weight reduction greater than or equal to 5% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
At week 52
Reported as:
Count of participants · Participants
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 5% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes11117
No1849
SecondaryParticipants Achieving Body Weight Reduction Greater Than or Equal (≥) 10% (Yes/No)

Participants who achieved body weight reduction greater than or equal to 10% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
At week 52
Reported as:
Count of participants · Participants
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 10% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes955
No3461
SecondaryParticipants Achieving Body Weight Reduction Greater Than or Equal (≥) 15% (Yes/No)

Participants who achieved body weight reduction greater than or equal to 15% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
At week 52
Reported as:
Count of participants · Participants
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 15% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes621
No6765
SecondaryParticipants Achieving Body Weight Reduction Greater Than or Equal (≥) 20% (Yes/No)

Participants who achieved body weight reduction greater than or equal to 20% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
At week 52
Reported as:
Count of participants · Participants
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 20% (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes320
No9766
SecondaryChange in Pulse

Change in pulse from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.

Time frame:
From randomisation (week 0) to end of treatment (week 52)
Reported as:
Mean · beats per minute (bpm)
Change in Pulse
beats per minute (bpm)Semaglutide 2.4 mgPlacebo
Change in Pulse2 ± 100 ± 7

Adverse events

Collected over From randomisation (week 0) to week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 2.4 mg2/138 (1.4%)12/138 (8.7%)93/138 (67.4%)
Placebo0/69 (0%)6/69 (8.7%)30/69 (43.5%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventSemaglutide 2.4 mgPlacebo
Atrial fibrillationCardiac disorders0/1381/69
Atrial flutterCardiac disorders0/1381/69
Chest painGeneral disorders0/1381/69
Embedded deviceProduct Issues0/1381/69
EndophthalmitisInfections and infestations0/1381/69
HypertensionVascular disorders0/1381/69
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1381/69
Pancreatitis acuteGastrointestinal disorders2/1380/69
Submandibular abscessInfections and infestations0/1381/69
TachycardiaCardiac disorders0/1381/69
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSemaglutide 2.4 mgPlacebo
COVID-19Infections and infestations48/13821/69
NauseaGastrointestinal disorders40/1383/69
ConstipationGastrointestinal disorders25/1380/69
DiarrhoeaGastrointestinal disorders17/1387/69
VomitingGastrointestinal disorders16/1381/69
DyspepsiaGastrointestinal disorders12/1383/69
Decreased appetiteMetabolism and nutrition disorders11/1381/69
HeadacheNervous system disorders6/1385/69
Abdominal pain upperGastrointestinal disorders7/1384/69
DizzinessNervous system disorders7/1381/69

Baseline characteristics

Full analysis set (FAS) included all the randomised participants.

Age, Continuous
Age, Continuous(Years)Semaglutide 2.4 mgPlaceboTotal
Mean53 ± 1153 ± 1153 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 2.4 mgPlaceboTotal
Female10047147
Male382260
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
Hispanic or Latino617
Not Hispanic or Latino13268200
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Semaglutide 2.4 mgPlaceboTotal
White12459183
Asian459
Black or African American639
Other415
American Indian or Alaska Native011
08

Study locations

43 sites
  • LMC Clin Res Inc. Calgary
    Calgary, Alberta T2H 2G4, Canada
  • University of Calgary
    Calgary, Alberta T2T 5C7, Canada
  • C-endo Diab Endo Clin Calgery
    Calgary, Alberta T2V 4J2, Canada
  • Weight Wise Clinic
    Edmonton, Alberta T6G 2R3, Canada
  • Ocean West Research Clinic
    Surrey, British Columbia V3Z 2N6, Canada
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Nova Scotia Hlth Halifax
    Halifax, Nova Scotia B3H 2Y9, Canada
  • LMC Diabetes & Endocrinology (Barrie)
    Barrie, Ontario L4N 7L3, Canada
  • LMC ClinRsrh Inc.Brampton
    Brampton, Ontario L6S 0C6, Canada
  • LMC Clin Res Inc. Thornhill
    Concord, Ontario L4K 4M2, Canada
  • LMC Endo Ctr (Etobicoke) Ltd
    Etobicoke, Ontario M9R 4E1, Canada
  • Wharton Med Clin Trials
    Hamilton, Ontario L8L 5G8, Canada
  • Premier Clinical Trial Research Network (PCTRN)
    Hamilton, Ontario L8M 1K7, Canada
  • Milestone Research
    London, Ontario N5W 6A2, Canada
  • LMC Research Inc. Ottawa
    Nepean, Ontario K2J 0V2, Canada
  • LMC Clinical Research Inc. Oakville
    Oakville, Ontario L6M 1M1, Canada
  • Centricity Research LMC
    Toronto, Ontario M4G 3E8, Canada
  • Toronto Sleep Institute/MedSleep
    Toronto, Ontario M4P 1P2, Canada
  • Diabetes Heart Research Centre
    Toronto, Ontario M6G 1M2, Canada
  • Dr Anil K Gupta Med Prof Corp
    Toronto, Ontario M9V 4B4, Canada
  • Manna Research Mirabel
    Mirabel, Quebec J7J 2K8, Canada
  • Centre Medical Acadie
    Montreal, Quebec H4N 2W2, Canada
  • Clinique Medicine Urbaine du Quartier Latin, Inc.
    Montreal, Quebec QC H2L 4E9, Canada
  • LMC Clin Rsrch Inc. (Montreal)
    Saint-Laurent, Quebec H4T 1Z9, Canada
  • Centre de recherché du CHUS
    Sherbrooke, Quebec J1H 5N4, Canada
  • Ctr de Med Metab de Lanaudiere
    Terrebonne, Quebec J6X 4P7, Canada
  • CHU de Quebec-Universite Laval
    Québec, G1V 4G2, Canada
  • Institut universitaire de cardiologie
    Québec, G1V 4G5, Canada
  • Aarhus Universitetshospital Diabetes og Hormonsygdomme
    Aarhus N, 8200, Denmark
  • Hvidovre Hospital Endokrinologisk forsknings afsnit 159
    Hvidovre, 2650, Denmark
  • Obesity Research Unit
    Helsinki, 00014, Finland
  • StudyCor
    Jyväskylä, 40620, Finland
  • Hospital Gregorio Marañón
    Madrid, 28009, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Infanta Luisa
    Seville, 41010, Spain
  • Clifton Medical Centre
    Rotherham, South Yorkshire S65 1DA, United Kingdom
  • The Health Centre
    Bradford-on-Avon, BA15 1DQ, United Kingdom
  • University Hospital Coventry - WISDEM Centre
    Coventry, CV2 2DX, United Kingdom
  • Claremont Medical Practice
    Exmouth, EX8 2JF, United Kingdom
  • GP Direct
    Harrow, HA2 0RQ, United Kingdom
  • Guys Hospital
    London, SE1 9RT, United Kingdom
  • The Staploe Medical Centre
    Soham, CB7 5JD, United Kingdom
  • MyHealth - Strensall Health Care Centre
    Strensall, YO32 5UA, United Kingdom
09

References and documents

Publications

  • McGowan BM, Bruun JM, Capehorn M, Pedersen SD, Pietilainen KH, Muniraju HAK, Quiroga M, Varbo A, Lau DCW; STEP 10 Study Group. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024 Sep;12(9):631-642. doi: 10.1016/S2213-8587(24)00182-7. Epub 2024 Jul 29. PubMed 39089293 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jan 2023, 16 months.

Results were first posted in Oct 2024, 1 year 9 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 16 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Sep 10, 2021
StartActual
Sep 6, 2021
Primary completionActual
Jan 6, 2023
CompletionActual
Jul 14, 2023
Results first posted
Oct 28, 2024
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05040971
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 10, 2021
Start date
Sep 6, 2021
Primary completion
Jan 6, 2023
Completion
Jul 14, 2023
Results posted
Oct 28, 2024
Last update
Jan 29, 2026

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion